Nicotine Replacement Therapy Market 2021 Latest Trends, Demand, Growth,
COVID-19 Impact, Opportunities & Outlook till 2028
The global nicotine replacement therapy market size was valued at USD 44.2 billion in 2020
and is expected to expand at a compound annual growth rate (CAGR) of 16.3% from 2021 to
2028. The growth can be attributed to the growing number of technological advancements
and the increasing number of people undergoing nicotine replacement therapy (NRT).
Increasing awareness about the ill-effects of smoking is expected to be a key factor driving
May 31st is celebrated as the No Tobacco Day and organizations such as the American Lung
Association and the CDC work toward increasing awareness about the medical conditions
that arise due to smoking. As per the NHS, 70% cases of lung cancer cases are a result of
smoking. Furthermore, smokers are more prone to getting heart attacks. Annually, 480,000
people in the U.S. die because of smoking. The CDC runs a paid national campaign called
the Tips From Former Smokers (Tips) to encourage healthcare providers to tell patients about
the effects of smoking and support them in quitting smoking in safe ways.
Key Player Mentioned:
Philip Morris Products S.A. (Altria Group)
British American Tobacco p.l.c.
Japan Tobacco, Inc.
Johnson & Johnson Services, Inc.
To identify the key drivers and the competitors’ insights, Request a Sample @:
Product Segment Analysis:
Nicotine Replacement Therapy
o Transdermal Patches
o Sublingual Tablets
Regional Segment Analysis: North America, Europe, Asia Pacific, Latin America, and Mideast
Technological advancements in the nicotine replacement therapy segment are ongoing, which
has led to a rise in the number of people switching to a